Flutamide is available as 250 mg tablets. It is an anti-androgen that inhibits the action of testosterone. It is primarily used in the treatment of prostate cancer. As an anti-androgen, it has also been used in the treatment of acne and excessive hair growth in women.
Indications of Flutamide:
-
Prostate carcinoma:
- It is indicated for the management of locally confined Stage B to C and Stage D metastatic prostate cancer (in combination with a luteinizing hormone-releasing hormone [LHRH] agonist).
- For Stage B to C prostate cancer, flutamide treatment (and goserelin) should start 8 weeks before starting radiation therapy and continue during radiation therapy.
- For maximum treatment benefit in Stage D metastatic prostate cancer, flutamide therapy should be started with the LHRH agonist and continued until disease progression.
Bicalutamide (Casodex) is another anti-androgen used in the treatment of prostate cancer.
Flutamide dose in adults:
Flutamide dose in the treatment of metastatic prostate cancer:
- 250 mg per oral three times a day (every 8 hours).
Use in Children:
Not indicated.
Pregnancy Risk Factor D
- Studies on animal reproduction revealed negative outcomes.
- Therapy can cause fetal harm during pregnancy.
- It is not recommended for use by women.
Flutamide use during breastfeeding:
- According to the manufacturer, it is not recommended for use by women.
- It is not possible to find information about its use by breastfeeding mothers.
Dose adjustment in renal disease:
No dosage adjustment is necessary for patients with chronic renal insufficiency.
Flutamide Dose adjustment in liver disease:
-
Mild to moderate impairment:
- There are no dosage adjustments provided in the manufacturer’s labeling.
-
Severe impairment:
- Use is contraindicated.
Common Side Effects of Flutamide:
-
Endocrine & Metabolic:
- Hot Flash
- Galactorrhea
- Decreased Libido
- Increased Lactate Dehydrogenase
-
Gastrointestinal:
- Diarrhea
- Vomiting
-
Genitourinary:
- Impotence
- Cystitis
- Breast Tenderness
-
Hematologic & Oncologic:
- Rectal Hemorrhage
- Tumor Flare
-
Hepatic:
- Increased Serum AST
Rare Side Effects Of Flutamide:
-
Cardiovascular:
- Edema
- Hypertension
-
Central Nervous System:
- Anxiety
- Confusion
- Depression
- Dizziness
- Drowsiness
- Headache
- Insomnia
- Nervousness
-
Dermatologic:
- Skin Rash
- Ecchymoses
- Pruritus
-
Endocrine & Metabolic:
- Gynecomastia
-
Gastrointestinal:
- Nausea
- Proctitis
- Gastric Distress
- Anorexia
- Constipation
- Dyspepsia
- Increased Appetite
-
Genitourinary:
- Hematuria
-
Hematologic & Oncologic:
- Anemia
- Leukopenia
- Thrombocytopenia
-
Infection:
- Herpes Zoster
-
Neuromuscular & Skeletal:
- Weakness
Contraindications to Flutamide:
Hypersensitivity to any drug or component of the formulation Severe liver dysfunction (evaluate baseline enzymes before treatment).
Warnings and precautions
-
Gynecomastia
- Males can experience gynecomastia by using flutamide therapy with medical castration.
-
Hepatic failure: [U.S. Boxed Warning]:
- Flutamide therapy can cause transaminitis and hepatic-encephalopathy, as well as jaundice and transaminitis.
- Flutamide therapy is 50% effective in reducing hepatotoxicity within the first three months. In some cases, stopping the therapy can reverse hepatotoxicity.
- Monitoring serum transaminase levels at baseline should be done monthly for four months and then periodically thereafter.
- Liver function tests should be performed if you have symptoms such as nausea, vomiting, stomach pain, fatigue, anorexia or "flu-like", jaundice, right upper quadrant tenderness and raised bilirubin. This is consistent with hepatic dysfunction.
- Therapy should be stopped for patients with ALT values exceeding 2x the upper normal limit.
- Therapy should be stopped immediately if ALT is above 2x the upper normal limit.
- Hospitalization for liver dysfunction can lead to death, but it is not common.
- Therapy is not recommended for patients suffering from severe hepatic impairment.
-
Cardiovascular disease
- Therapy with androgen deprivation increases the risk of cardiovascular disease.
-
Hemoglobin M Disease:
- Patients with hemoglobin M disorder have a significantly higher risk of developing toxicities from aniline exposure.
- Therefore, it is important to monitor methemoglobin levels closely.
Flutamide: Drug Interaction
Risk Factor C (Monitor therapy) |
|
Abiraterone Acetate |
May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors). |
Broccoli |
May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers). |
Cannabis |
May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers). |
Choline C 11 |
Antiandrogens may diminish the therapeutic effect of Choline C 11. |
CYP1A2 Inducers (Moderate) |
May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers). |
CYP1A2 Inhibitors (Moderate) |
May decrease the metabolism of CYP1A2 Substrates (High risk with Inhibitors). |
Cyproterone |
May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers). |
Dapsone (Topical) |
May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. |
Deferasirox |
May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors). |
Local Anesthetics |
Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. |
Nitric Oxide |
May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when nitric oxide is used in combination with other agents associated with development of methemoglobinemia. Avoid lidocaine/prilocaine. |
Obeticholic Acid |
May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors). |
Peginterferon Alfa-2b |
May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors). |
Prilocaine |
Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia. Avoid lidocaine/prilocaine in infants receiving such agents. |
Sodium Nitrite |
Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. |
Teriflunomide |
May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers). |
Risk Factor D (Consider therapy modification) |
|
CYP1A2 Inhibitors (Strong) |
May decrease the metabolism of CYP1A2 Substrates (High risk with Inhibitors). |
Vemurafenib |
May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors). Management: Consider alternatives to such combinations whenever possible, particularly if the CYP1A2 substrate has a relatively narrow therapeutic index. Drugs listed as exceptions to this monograph are discussed in separate drug interaction monographs. |
Risk Factor X (Avoid combination) |
|
Indium 111 Capromab Pendetide |
Antiandrogens may diminish the diagnostic effect of Indium 111 Capromab Pendetide. |
Monitoring parameters:
- PSA (prostate-specific antigen LFTs monitoring in case of symptoms including nausea, vomiting, abdominal pain, fatigue, anorexia, flu-like symptoms, hyperbilirubinemia, jaundice, or right upper quadrant tenderness. Serum transaminases (at baseline, monthly for 4 months, and periodically thereafter).
How to administer Flutamide?
It can be taken orally with or without food. It should be given in three divided doses.
Mechanism of action of Flutamide:
Nonsteroidal antiandrogen, it works by blocking androgen uptake in the target tissues and/or inhibiting androgen binding.
Absorption: Oral:
- Rapid and complete.
Protein binding:
- Parent drug: 94% to 96%; 2-hydroxyflutamide: 92% to 94%.
Metabolism:
- Extensively hepatic to ≥6 metabolites, primarily 2-hydroxyflutamide (active).
Half-life elimination:
- 6 hours (2-hydroxyflutamide).
Time to peak:
- 2 hours (2-hydroxyflutamide).
Excretion:
- Primarily urine (as metabolites);
- feces (~4%).
International Brands of Flutamide:
- DOM-Flutamide
- Euflex
- NU-Flutamide
- PMS-Flutamide
- TEVA-Flutamide
- Androxine
- Bedozane
- Curestat
- Cytomid
- Cytomid-250
- Drogenil
- Etaconil
- Eulexin
- Eulexine
- Eumide
- Flucinom
- Flucinome
- Flugerel
- Fluken
- Flulem
- Flumid
- Fluta-Cell
- Flutacan
- Flutafarm
- Flutam
- Flutamex
- Flutamid
- Flutamid Abbott
- Flutamin
- Flutan
- Flutanon
- Flutaplex
- Flutasin
- Flutax
- Flutexine
- Flutrax
- Fluxus
- Fugerel
- Fuprostatel
- Grisetin
- Profamid
- Proscant
- Prostacur
- Prostalex
- Prostica
- Tafenil
Flutamide brands in Pakistan:
Flutamide Tablets 250 mg |
|
Elbat | Rotex Medica, Germany |
Flutamida Gador | Seignior Pharma |
Fluten | Pharmedic (Pvt) Ltd. |